Regeneron Pharmaceuticals, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +75

Fund Update: New $14.8M $REGN stock position opened by Vest Financial, LLC - Quiver Quantitative

AI-generated analysis

πŸ“Š Vest Financial, LLC opened a new $14.8 million position in Regeneron Pharmaceuticals ($REGN) stock according to an SEC 13F filing.

πŸ“… This disclosure reflects the fund's holdings as of the March 31, 2026 reporting period.

🀝 A total of 688 institutional investors have added shares of $REGN to their portfolios in the most recent quarter.

βž– Conversely, 578 institutional investors decreased their positions in $REGN during the same timeframe.

🏒 Insiders have traded $REGN stock 44 times over the past six months, with all trades being sales and no purchases.

πŸ‘¨β€βš–οΈ Members of Congress have executed two trades in $REGN stock over the past six months, both of which were purchases.

πŸ“ˆ Wall Street analysts have issued buy ratings on $REGN from 7 firms with no sell ratings recorded recently.

🎯 Twenty analysts have provided price targets for $REGN in the last six months, with a median target set at $862.50.

⚠️ Users are advised that estimates may contain inaccuracies due to filing errors or parsing anomalies.

πŸ”— Full portfolio details and institutional holder tracking are available via Quiver Quantitative's dashboard.

Bullish Signals
  • Vest Financial, LLC has opened a new $14.8M position in REGN stock, indicating strong institutional confidence.
  • We have seen 688 institutional investors add shares of REGN stock to their portfolio in the most recent quarter.
  • Members of Congress have purchased REGN stock 2 times in the past 6 months with zero sales, demonstrating continued bullish sentiment.
  • Wall Street analysts are overwhelmingly positive on REGN, with 7 firms issuing buy ratings and 0 firms issuing sell ratings.
  • Multiple analysts have set a median price target of $862.5 for REGN stock over the last 6 months.
Risk Factors
  • Despite institutional interest, REGN insiders have only sold 44 shares of the stock over the past six months with zero purchases, suggesting a lack of confidence among inside management.
  • A net outflow from insider trading indicates that company insiders are divesting their holdings rather than accumulating more shares in $REGN.
Full Analysis
Vest Financial, LLC has disclosed the opening of a new $14.8 million position in Regeneron Pharmaceuticals Inc. ($REGN) in its most recent SEC 13F filing for the period ending March 31, 2026. This institutional investment adds to recent market activity where 688 institutional investors increased their holdings of $REGN while 578 decreased theirs during the same quarter. The filing was reported by Quiver Quantitative, which tracks institutional ownership and provides detailed portfolio breakdowns for funds like Vest Financial. Insider trading activity for Regeneron has been predominantly negative over the past six months, with corporate insiders executing 44 trades on the open market. All 44 of these transactions were sales, with zero purchases recorded by company insiders during this timeframe. In contrast, members of Congress have shown bullish sentiment with two purchases and no sales regarding $REGN stock in the same period. Analyst sentiment remains positive, with seven Wall Street firms issuing buy ratings on Regeneron Inc. without any sell ratings issued recently. A total of 20 analysts have provided price targets for the stock over the last six months, resulting in a median target price of $862.50 per share. While Quiver Quantitative aggregates this data to track market sentiment and forecast prices, they note that some estimates may contain inaccuracies due to potential filing errors by funds or parsing anomalies in their system.